Cytek Biosciences, Inc. $CTKB Stock Position Boosted by Russell Investments Group Ltd.

Russell Investments Group Ltd. raised its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 60.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,428,747 shares of the company’s stock after acquiring an additional 917,432 shares during the quarter. Russell Investments Group Ltd.’s holdings in Cytek Biosciences were worth $14,475,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of CTKB. BlackRock Inc. purchased a new stake in Cytek Biosciences in the second quarter worth $42,433,000. Hhlr Advisors LTD. purchased a new stake in shares of Cytek Biosciences during the second quarter valued at $29,491,000. Dimensional Fund Advisors LP boosted its stake in shares of Cytek Biosciences by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,663,329 shares of the company’s stock valued at $11,638,000 after purchasing an additional 16,438 shares during the period. Bank of America Corp DE purchased a new stake in shares of Cytek Biosciences during the second quarter valued at $5,827,000. Finally, Susquehanna International Group LLP grew its holdings in shares of Cytek Biosciences by 1,117.1% in the second quarter. Susquehanna International Group LLP now owns 681,705 shares of the company’s stock worth $3,020,000 after purchasing an additional 625,695 shares during the last quarter. Institutional investors own 69.46% of the company’s stock.

Cytek Biosciences Stock Up 6.8%

CTKB opened at $6.32 on Friday. The stock’s fifty day moving average is $5.60 and its two-hundred day moving average is $4.70. The company has a market capitalization of $826.53 million, a P/E ratio of -10.03 and a beta of 1.15. Cytek Biosciences, Inc. has a 52 week low of $3.31 and a 52 week high of $6.34.

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. Cytek Biosciences had a negative return on equity of 13.13% and a negative net margin of 39.10%. The business had revenue of $53.23 million during the quarter, compared to analysts’ expectations of $53.05 million. Equities analysts anticipate that Cytek Biosciences, Inc. will post -0.28 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on CTKB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytek Biosciences in a research note on Monday, September 21st. Wall Street Zen raised shares of Cytek Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Morgan Stanley set a $5.00 price objective on shares of Cytek Biosciences in a research report on Friday, August 7th. Finally, Stephens upped their target price on shares of Cytek Biosciences from $6.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cytek Biosciences currently has an average rating of “Hold” and a consensus target price of $5.67.

Get Our Latest Stock Report on Cytek Biosciences

Cytek Biosciences Company Profile

(Free Report)

Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company’s product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.

Featured Articles

Want to see what other hedge funds are holding CTKB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report).

Institutional Ownership by Quarter for Cytek Biosciences (NASDAQ:CTKB)

Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.